Table 1.
Demographic and Clinical Characteristics of Patients in the Study
| Characteristics | Training Cohort | Validation Cohort | p value |
|---|---|---|---|
| Endoscopic procedures | 332 | 183 | |
| Gender, male | 242 (72.9) | 127 (69.4) | 0.400 |
| Age at endoscopic procedures, year | 28.0 (21.9–36.0) | 26.0 (22.0–33.0) | 0.264 |
| Age at diagnosis, year | 0.603 | ||
| A1: ≤16 | 48 (14.5) | 22 (12.0) | |
| A2: 17–40 | 235 (70.8) | 137 (74.9) | |
| A3: >40 | 49 (14.7) | 24 (13.1) | |
| CD location | 0.268 | ||
| L1: Ileal | 68 (20.5) | 30 (16.4) | |
| L2: Colonic | 38 (11.4) | 16 (8.7) | |
| L3: Ileocolonic | 226 (68.1) | 137 (74.9) | |
| CD behaviour | 0.627 | ||
| B1: Non-stricturing, non-penetrating | 162 (48.8) | 95 (51.9) | |
| B2: Stricturing | 108 (32.5) | 52 (28.4) | |
| B3: Penetrating | 62 (18.7) | 36 (19.7) | |
| Perianal disease | 155 (46.7) | 80 (43.7) | 0.517 |
| History of CD-related surgery | 76 (22.9) | 28 (15.3) | 0.040 |
| BMI, kg/m2 | 18.3 (16.8–20.5) | 19.0 (16.9–20.7) | 0.304 |
| Medication | |||
| 5-aminosalicylic acid | 65 (19.6) | 32 (17.5) | 0.561 |
| Thiopurine | 58 (17.5) | 48 (26.2) | 0.019 |
| Thalidomide | 26 (7.8) | 7 (3.8) | 0.076 |
| Corticosteroids | 15 (4.5) | 10 (5.5) | 0.632 |
| Anti-TNF agents | 59 (17.8) | 31 (16.9) | 0.812 |
| SES-CD | 7 (3–16) | 7 (4–15) | 0.999 |
| Endoscopic remission | 61 (18.4) | 32 (17.5) | 0.965 |
| Endoscopic activity | |||
| Mild activity (SES-CD: 3–6) | 93 (28.0) | 51 (27.9) | |
| Moderate activity (SES-CD:7–15) | 93 (28.0) | 55 (30.0) | |
| Severe activity (SES-CD ≥16) | 85 (25.6) | 45 (24.6) |
Notes: Continuous and categorical variables are presented as median (interquartile range) and n (%), respectively.
Abbreviations: CD, Crohn’s disease; BMI, body mass index; Anti-TNF, anti-tumour necrosis factor; SES-CD, simple endoscopic score for Crohn’s disease.